< div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " > KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " >..."> < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " > KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " >..." /> < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " > KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " >..." />

Data for Merck ' s Investigational Once-Daily Formulation of ISENTRESS ® (raltegravir) Show That at Week 48, a Regimen Containing the Once-Daily Dosing Formulation...

< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " > KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " > < div class= " field-items " > < div class= " field-item odd " > < p > Resulted in Non-Inferior Efficacy and Safety to a Regimen Containing the Approved Twice-Daily Formulation < /p > < p > EMA Accepts File Application, Plans Underway to Submit for Licensure to FDA This Year < /p > < /div > < /div > < /div > < p > KENILWORTH, N.J.--( < a target= " _blank " href= " http://www.businesswire.com " > BUSINESS WIRE < /a > )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced efficacy and safety data in previously untreated adults with HIV-1 infection for the company ’s investigational once-daily formulation of ISENTRESS < sup > ® < /sup > (raltegravir), known as raltegravir 600 mg (to be given as 2 x 600 mg), from the ongoing Phase 3 pivotal trial called ONCEMRK. < /p > < div class= " field field-type-text field-field-press-release-language field-fieldpressreleaselanguage " > < div class= " field-label " > Language: < /div > < div class= " field-items " > < div class= " field-item odd " ...
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK HIV ISENTRESS MSD NYSE:MRK Source Type: news